There are currently no FDA-approved therapies for NASH. Many investigational treatments aim to reduce inflammation and fibrosis, but have demonstrated little improvement in addressing the underlying metabolic drivers of the disease. In addition, some investigational treatments do not improve dyslipidemia—including hypercholesterolemia and hypertriglyceridemia—which underlies NASH patients’ susceptibility to cardiovascular disease.
We believe EFX is a powerful new therapy that has the potential to reverse the underlying metabolic dysregulation of the liver, protect against hepatocyte stress, and suppress downstream inflammation and fibrosis, with the ultimate goal of resolving NASH and restoring a healthy liver.
We recently announced key results from our Phase 2a trial, the BALANCED study. Specifically, we reported that patients treated with EFX achieved reductions in liver fat and reversals of fibrosis that rank among the largest reported across all NASH trials. EFX patients also achieved weight loss and improvements in lipid profiles and glycemic control. The study results exceeded expectations and pave the way for the next stage of development.